USANA Health Sciences (NYSE:USNA) Upgraded at Zacks Research

Zacks Research upgraded shares of USANA Health Sciences (NYSE:USNA) from a strong sell rating to a hold rating in a report issued on Monday morning,Zacks reports.

Several other equities analysts also recently issued reports on USNA. Wall Street Zen downgraded shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, September 21st. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, USANA Health Sciences currently has a consensus rating of “Reduce”.

USANA Health Sciences Price Performance

USANA Health Sciences stock opened at $14.70 on Monday. The stock has a market capitalization of $271.71 million, a price-to-earnings ratio of -12.15, a PEG ratio of 1.63 and a beta of 0.68. USANA Health Sciences has a 1-year low of $12.57 and a 1-year high of $26.76. The business has a fifty day moving average price of $14.99 and a 200-day moving average price of $17.84.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.50). USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. The business had revenue of $223.27 million for the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. On average, equities research analysts anticipate that USANA Health Sciences will post 0.76 earnings per share for the current fiscal year.

Institutional Trading of USANA Health Sciences

A number of hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc grew its holdings in USANA Health Sciences by 1,472.3% during the second quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock worth $34,000 after acquiring an additional 1,487 shares during the period. State of Wyoming purchased a new stake in USANA Health Sciences in the 1st quarter worth approximately $57,000. DGS Capital Management LLC purchased a new stake in USANA Health Sciences in the 1st quarter worth approximately $208,000. GSA Capital Partners LLP acquired a new stake in shares of USANA Health Sciences during the 2nd quarter worth approximately $250,000. Finally, First Trust Advisors LP increased its holdings in shares of USANA Health Sciences by 17.7% during the 1st quarter. First Trust Advisors LP now owns 14,784 shares of the company’s stock valued at $258,000 after purchasing an additional 2,227 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and sells nutritional supplements, personal-care products and foods designed to support general health and wellness. Its product portfolio includes vitamins and mineral supplements, herbal and specialty nutritional products, meal-replacement and snack items, and skincare products marketed under the USANA and Sensé brands.

Founded in 1992 by immunologist Myron Wentz, USANA distributes its products primarily through a direct-selling model involving independent associates.